SELECT ISSUE

MÆDICA - a Journal of Clinical Medicine | Vol. 9, nr. 3, 2014

ISSN 1841-9038  |  e-ISSN 2069-6116
ISSN-L 1841-9038
CNCSIS - CMR - B+

Gene Therapy and Cardiomyocyte Transplant in Heart Failure

Since decades, prognosis in advanced heart failure is considered as bad as in cancer.

One reason is that two or three decades before cancer was considered incurable. Now there are curable cancers, but a lot of incurable as well. Today congestive heart failure rested incurable almost in the totality of cases. We may try to treat the cause, like ischemia, but if heart failure is installed, the force of the ventricle will not be restored. We may use good drugs or devices, but it is just a physiopathological approach. The real mechanism by which heart myofibrils lose their inotropism is not well understood and, consequently, not treated.

But a new therapeutic era for heart failure seems to be ready to be applied in humans: gene therapy, with action on potential subcellular targets to improve contractility of existing myofibrils (1-3) or cardiomyocyte transplant (4- 6). Both ways have large studies on animals, but there are clinical studies on humans as well (3,6).

Full text | PDF